Abstracts tagged "glucocorticoids"

Abstract Number: 1083 • ACR Convergence 2020
Alterations of Lipid Profile in IIM Patients Are Associated with Disease Activity, Duration, and Glucocorticoid Treatment
Sabina Oreska¹, Hana Storkanova², Maja Spiritovic³, Barbora Hermankova⁴, Michal Vrablik⁵, Karel Pavelka⁶, Ladislav Šenolt⁶, Heřman Mann², Jiří Vencovský⁶ and Michal Tomcik⁷, ¹Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha 2, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Faculty of Physical Education and Sport, Department of Physiotherapy, Charles University, Prague, Czech Republic,, Prague, Czech Republic, ⁵3rd Department of Internal Medicine, General University Hospital, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by skeletal muscle and organ involvement and chronic course. Systemic inflammation, limited mobility, and glucocorticoid treatment can have…
Abstract Number: 1998 • ACR Convergence 2020
Ten-year Analysis of the Risk of Severe Outcomes Related to Very Low-dose Glucocorticoids in Early Rheumatoid Arthritis
Camille Roubille¹, Amandine Coffy², Nathalie Rincheval², Jean Pierre Daures², René-Marc Flipo³, Maxime Dougados⁴ and Bernard Combe⁵, ¹CHU LAPEYRONIE, Montpellier, France, ²INSERM, Montpellier, France, ³Univ-Lille, CHU Lille, department of rheumatology, Lille, France, ⁴Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, ⁵University of Montpellier, Montpellier, France
Background/Purpose: Although glucocorticoids (GC) remain an essential part of the therapeutic strategy in Rheumatoid Arthritis (RA), the long-term risk of adverse events of low-dose GC…
Abstract Number: 0016 • ACR Convergence 2020
Differential Characteristics in Inflammatory Rheumatologic Patients with Severe and Mild COVID-19 Infection
Paula García Escudero¹, Claudia Stoye², Orlando Pompei fernández², Marta González Fernández¹, Joaquín María Belzunegui Otano³, Juan Ramón De Dios², Belén Álvarez Rodríguez², Elena Garmendia Sánchez¹, Susana Gil², Ana Ruibal-Escribano⁴, Margarida Vasques Rocha², Francisco García Llorente⁵, César Antonio Egües⁶, Edurne Guerrero⁷ and Jaime Calvo-Alén², ¹Hospital Universitario Cruces, Barakaldo, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, ⁴Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ⁵Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, ⁶Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, ⁷Hospital Alto Deba, Arrasate, Pais Vasco, Spain
Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
Abstract Number: 1224 • ACR Convergence 2020
Glucocorticoid Reduction in Different Profiles of Patients with Rheumatoid Arthritis and Treatment with Sarilumab
Esteban Rubio Romero¹, Alejandro Muñoz Jiménez², Rosalia Martinez Perez³ and Lara Mendez Diaz⁴, ¹VIRGEN DEL ROCIO UNIVERSITY HOSPITAL, SEVILLE, Spain, ²H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, ³Virgen del Rocío University Hospital, seville, Spain, ⁴Virgen del Rocío Hospital, sevilla, Spain
Background/Purpose: Glucocorticoid reduction in different profiles of patients with rheumatoid arthritis and sarilumab treatment. Real clinical practice studies are tasked with providing clinically relevant data…
Abstract Number: 2008 • ACR Convergence 2020
Should We Use Glucocorticoid in Early Rheumatoid Arthritis? : Results at 5 Years from the ERA Louvain Brussels Cohort
Emilie Sapart¹, Tatiana Sokolova¹, Stéphanie de Montjoye¹, Stéphanie Dierckx², Adrien Nzeusseu Toukap³, Aleksandra Avramovska¹ and Patrick Durez⁴, ¹Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Rheumatology, CHU Mont-Godinne, Mont Godinne, Belgium, ³1Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium, ⁴Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Background/Purpose: The EULAR recommendations, updated in 20161 and 20192, propose the initiation of glucocorticoid (GC) therapy in combination with cDMARDs background therapy for every patient…
Abstract Number: 0089 • ACR Convergence 2020
The Risk Factors of Recurrence in Relapsing Polychondritis; A Study of 41 Cases
Tsuneyasu Yoshida¹, Hajime Yoshifuji², Mirei Shirakashi¹, Koji Kitagori¹, Shuji Akizuki², Ran Nakashima¹, Kosaku Murakami¹, Motomu Hashimoto³, Masao Tanaka³ and Koichiro Ohmura¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Japan, ³Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan
Background/Purpose: Relapsing polychondritis (RP) is a rare disease which causes inflammation in systemic cartilages. Although glucocorticoids (GC) and immunosuppressive drugs (IS) have been used, the…
Abstract Number: 1442 • ACR Convergence 2020
Denosumab versus Oral Bisphosphonate for Osteoporosis in Long-term Glucocorticoid Users: A 12-month Randomized Controlled Trial
Chi Chiu Mok¹, Ling Yin Ho¹ and Kwok Man Ma¹, ¹Tuen Mun Hospital, Hong Kong, China (People's Republic)
Background/Purpose: To compare the efficacy of denosumab (DEN) and oral alendronate (ALN) on spinal bone mineral density (BMD) in long-term glucocorticoid users.Methods: Patients receiving long-term…
Abstract Number: 0109 • ACR Convergence 2020
Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
Eileen Rife¹, Emejuaiwe Nkechinyere² and Jose Leon de la Rocha³, ¹Louisiana State University, Metairie, LA, ²Department of Veterans Affairs, New Orleans, LA, ³Louisiana State University, Auburn, AL
Background/Purpose: Descriptive study designed to assess compliance to evidence-based practice guidelines for the prevention of Glucocorticoid-Induced Osteoporosis (GIOP).Methods: We queried the electronic database of the…
Abstract Number: 1590 • ACR Convergence 2020
Bone Health in ANCA – Associated Vasculitis Patients
Deepa Ragesh Panikkath¹, Sandy Lee² and Christina Downey², ¹Loma Linda University Health, Department of Rheumatology, Loma Linda, CA, ²Loma Linda University Medical Center, Redlands, CA
Background/Purpose: Glucocorticoids (GC) are an important mode of therapy in ANCA associated vasculitis (AAV), and osteoporosis (OP) and fractures are potential adverse effects seen. The…
Abstract Number: 0120 • ACR Convergence 2020
Risk of Fracture in Patients with Different Glucocorticoid Requiring Diseases
Giovanni Adami¹, Angelo Fassio², Alessandro Giollo², Luca Idolazzi², Ombretta Viapiana¹, Davide Gatti² and Maurizio Rossini², ¹University of Verona, Verona, Italy, ²Rheumatology Unit, University of Verona, Verona, Italy
Background/Purpose: The aim of the present work is to determine the fracture risk associated with glucocorticoids requiring diseasesMethods: We conducted a retrospective analysis of a nation-wide…
Abstract Number: 1739 • ACR Convergence 2020
Patients with Early Rheumatoid Arthritis Considered to Have a Favourable Risk Profile and Treated According to a Step-up Strategy Have an Increased Risk of Chronic Analgesic Consumption
Sofia Pazmino¹, Annelies Boonen², Diederik De Cock¹, Veerle Stouten¹, Delphine Bertrand¹, Johan Joly³, Rene Westhovens⁴ and Patrick Verschueren⁵, ¹KU Leuven, Leuven, Belgium, ²Maastricht University Medical Center, Maastricht, Netherlands, ³University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium, ⁴University Hospitals Leuven, Belgium, Leuven, Belgium, ⁵University Hospital Leuven, Leuven, Belgium
Background/Purpose: Pain remains the highest priority for improvement to patients with Rheumatoid Arthritis (RA). Analgesic prescription in RA was historically a stand-alone approach and afterwards…
Abstract Number: 0126 • ACR Convergence 2020
Immunophenotyping of Peripheral Blood Highlights an Association of Dysregulated Lymphocytes with Patients with Glucocorticoid-induced Osteonecrosis
Kaichi Kaneko¹, Hao Chen¹, Alexandra Krez², Steven Zeng¹, Peter Park¹, Ye-Ji Lee¹, Takayuki Fujii¹, Haemin Kim¹, Sehwan Mun¹, Seyeon Bae¹, Tania Pannellini³, Joseph Lane⁴, Derek Hansen⁴, Douglas Mintz⁵, Richard Bockman², Emily Stein⁶ and Kyung-Hyun Park-Min⁷, ¹Arthritis and Tissue Degeneration Program, David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ²Endocrine Service, Hospital for special surgery, New York, NY, ³Pathology and Precision Medicine Laboratory, Hospital for special surgery, New York, NY, ⁴Orthopedic surgery, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY, ⁵Radiology, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY, ⁶Endocrine Service, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY, ⁷Arthritis and Tissue Degeneration Program, David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, Department of Medicine, Weill Cornell Medical College, New York, NY
Background/Purpose: Avascular necrosis (AVN) is a musculoskeletal condition that can result in significant pain and compromised quality of life. The diverse etiologies of AVN have…
Abstract Number: 1743 • ACR Convergence 2020
Perioperative Steroids in Rheumatoid Arthritis Patients Having Total Joint Replacements: Help or Harm?
Tariq Chukir¹, Susan Goodman², Haley Tornberg³, Huong Do⁴, Charlene Thomas⁵, Alana Sigmund³, Peter Sculco⁶, Bella Mehta⁶, Linda Russell⁶, Mark Figgie² and Emily Stein⁷, ¹Weill Cornell Medicine and New York Presbyterian Hospital, New York, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, ⁴Hospital for Special Surgery, New York, NY, ⁵Weill Cornell Medicine, New York, ⁶Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁷Endocrine Service, Hospital for special surgery, Department of Medicine, Weill Cornell Medical College, New York, NY
Background/Purpose: Optimal perioperative glucocorticoids (GC) dosing for rheumatoid arthritis (RA) patients on chronic GCs undergoing total joint replacement is unknown. Ideal GC dosing prevents perioperative…
Abstract Number: 1152 • 2019 ACR/ARP Annual Meeting
Low Rates of Bone Mineral Density Testing by Rheumatologists in Patients with Systemic Lupus Erythematosus and Glucocorticoid Therapy
JB Boone¹, S. Bobo Tanner ¹ and April Barnado ¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at an increased risk of developing osteoporosis and clinical fractures compared to healthy controls. Bone loss in…
Abstract Number: 1432 • 2019 ACR/ARP Annual Meeting
Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –
Shintaro Hirata¹, Takuji Omoto ¹, Hiroki Kohno ¹, Hirofumi Watanabe ¹, Kazutoshi Yukawa ¹, Tadahiro Tokunaga ¹, Tatsuomi Kuranobu ¹, Katsuhiro Oi ¹, Yusuke Yoshida ¹, Tomohiro Sugimoto ¹, Sho Mokuda ¹, Keisuke Oda ¹, Takaki Nojima ¹ and Eiji Sugiyama ¹, ¹Hiroshima University, Hiroshima, Japan
Background/Purpose: To determine whether prednisolone (PSL) could be tapered or discontinued without deterioration of disease control through optimizing methotrexate (MTX) for 2-yrs in patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].